Teva Q3 revenue up 7% to $3.9B, raises FY revenue guidance to $15.1-$15.5B

TEVA PHARMACEUTICAL INDUSTRIES LTD

2023-Q3 EPS reported -$0.88 revenue$11,389,000,000

Revenue $3.85B (+7% YoY); GAAP EPS $0.07, non-GAAP EPS $0.60.
Raised 2023 revenue outlook to $15.1-$15.5B from $15.0-$15.4B; reaffirms non-GAAP EPS $2.25-$2.55.
AUSTEDO and AJOVY drove growth; global generics revenues increased across all segments.
Entered exclusive collaboration with Sanofi on Anti TL1-A (TEV-'574) in October 2023.
Appointed Dr. R. Ananthanarayanan as CEO of Teva api; olanzapine LAI Phase 3 results now H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended September 30, 2023 results: revenue $3.9 billion, EPS GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.60. Guidance raised.

Period: the quarter ended September 30, 2023
Revenue: $3.9 billion
EPS: GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.60
Guidance: raised
Result: reported results

Exact text from the filing

Global revenues of $3.9 billion, reflect an increase of 7% from the third quarter of 2022 Increased revenues reflect sustained growth of AUSTEDO ® , AJOVY ® and global generics business: Growth of AUSTEDO in North America Growth of AJOVY globally Stable and sustainable generics business in the U.S.; continued growth in Europe and International Markets GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.60

View on SEC.gov

Browse all earnings releases →

TEVA PHARMACEUTICAL INDUSTRIES LTD filing history →

Source: SEC EDGAR

accession 0001157523-23-001677

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.